{"entity":"gilead-sciences","id":"ent_gilead-sciences","name":"Gilead Sciences","from":"2025-11-08","to":"2026-11-08","page":"https://asof.is/record/gilead-sciences/diff?from=2025-11-08&to=2026-11-08","summary":"Between 2025-11-08 and 2026-11-08, Gilead Sciences's record changed in 15 facts: 3 replaced (net income $480 million → $8.51 billion; operating income $1.66 billion → $10.02 billion; revenue $28.75 billion → $29.44 billion), 6 added, 6 ended; 13 unchanged.","counts":{"changed":15,"added":6,"ended":6,"replaced":3,"unchanged":13,"skipped_posts":{"from":0,"to":0}},"by_predicate":[{"predicate":"quarterly_net_income","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_operating_income","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_revenue","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"shares_outstanding","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"total_assets","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"total_equity","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"net_income","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"operating_income","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"revenue","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"cash_and_equivalents","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"cik","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"fiscal_year_end","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"headquarters","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"listed_on","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"quarterly_research_and_development","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"registrant_name","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"research_and_development","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"sic_industry","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"state_of_incorporation","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"ticker","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"website","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"x_username","added":0,"ended":0,"replaced":0,"unchanged":1}],"added":[{"id":"clm_4B6581046BE2","predicate":"quarterly_net_income","value":"2,429,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 2,429,000,000 United States dollar\", as of 2026-09-30. Claim clm_4B6581046BE2, https://asof.is/claim/clm_4B6581046BE2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.","url":"https://asof.is/claim/clm_4B6581046BE2","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_8490C244F9F5","predicate":"quarterly_operating_income","value":"3,462,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 3,462,000,000 United States dollar\", as of 2026-09-30. Claim clm_8490C244F9F5, https://asof.is/claim/clm_8490C244F9F5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.","url":"https://asof.is/claim/clm_8490C244F9F5","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_64E20B8C7E0A","predicate":"quarterly_revenue","value":"8,300,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 8,300,000,000 United States dollar\", as of 2026-09-30. Claim clm_64E20B8C7E0A, https://asof.is/claim/clm_64E20B8C7E0A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.","url":"https://asof.is/claim/clm_64E20B8C7E0A","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_3ADDE79BC725","predicate":"shares_outstanding","value":"1,240,338,614 shares","valid_from":"2026-10-23","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,240,338,614 shares\", as of 2026-10-23. Claim clm_3ADDE79BC725, https://asof.is/claim/clm_3ADDE79BC725, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.","url":"https://asof.is/claim/clm_3ADDE79BC725","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_53C30342724D","predicate":"total_assets","value":"51,408,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 51,408,000,000 United States dollar\", as of 2026-09-30. Claim clm_53C30342724D, https://asof.is/claim/clm_53C30342724D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.","url":"https://asof.is/claim/clm_53C30342724D","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_F5C77DE07AFE","predicate":"total_equity","value":"13,040,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 13,040,000,000 United States dollar\", as of 2026-09-30. Claim clm_F5C77DE07AFE, https://asof.is/claim/clm_F5C77DE07AFE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.","url":"https://asof.is/claim/clm_F5C77DE07AFE","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-10-30"}}],"ended":[{"id":"clm_8C716505DCB2","predicate":"quarterly_net_income","value":"3,052,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 3,052,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_8C716505DCB2, https://asof.is/claim/clm_8C716505DCB2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_8C716505DCB2","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_24FF1FC3A935","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_E88E046C7258","predicate":"quarterly_operating_income","value":"3,327,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 3,327,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_E88E046C7258, https://asof.is/claim/clm_E88E046C7258, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_E88E046C7258","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3305AD308056","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_3A5203A42518","predicate":"quarterly_revenue","value":"7,769,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 7,769,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_3A5203A42518, https://asof.is/claim/clm_3A5203A42518, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_3A5203A42518","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5B00A751741D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_5E452E3F3A54","predicate":"shares_outstanding","value":"1,240,679,623 shares","valid_from":"2025-10-31","valid_to":"2026-02-13","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,240,679,623 shares\", as of 2025-10-31 (until 2026-02-13). Claim clm_5E452E3F3A54, https://asof.is/claim/clm_5E452E3F3A54, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_5E452E3F3A54","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E2DB5E0B53B4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_5B9243C901AF","predicate":"total_assets","value":"58,533,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 58,533,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_5B9243C901AF, https://asof.is/claim/clm_5B9243C901AF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_5B9243C901AF","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_06C160F8C3A5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_B2A4004D2607","predicate":"total_equity","value":"21,540,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 21,540,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_B2A4004D2607, https://asof.is/claim/clm_B2A4004D2607, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_B2A4004D2607","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_994B784F55A6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-11-07"}}],"replaced":[{"predicate":"net_income","from":{"id":"clm_D66A9204BCB4","predicate":"net_income","value":"480,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 480,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_D66A9204BCB4, https://asof.is/claim/clm_D66A9204BCB4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm.","url":"https://asof.is/claim/clm_D66A9204BCB4","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_075AC6F097D8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-28"}},"to":{"id":"clm_075AC6F097D8","predicate":"net_income","value":"8,510,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 8,510,000,000 United States dollar\", as of 2025-12-31. Claim clm_075AC6F097D8, https://asof.is/claim/clm_075AC6F097D8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm.","url":"https://asof.is/claim/clm_075AC6F097D8","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-24"}}},{"predicate":"operating_income","from":{"id":"clm_9D8D94D516C5","predicate":"operating_income","value":"1,662,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 1,662,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_9D8D94D516C5, https://asof.is/claim/clm_9D8D94D516C5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm.","url":"https://asof.is/claim/clm_9D8D94D516C5","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_44AE227A69DA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-28"}},"to":{"id":"clm_44AE227A69DA","predicate":"operating_income","value":"10,022,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 10,022,000,000 United States dollar\", as of 2025-12-31. Claim clm_44AE227A69DA, https://asof.is/claim/clm_44AE227A69DA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm.","url":"https://asof.is/claim/clm_44AE227A69DA","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2025, filed 2026-02-24"}}},{"predicate":"revenue","from":{"id":"clm_766F0DC2656D","predicate":"revenue","value":"28,754,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 28,754,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_766F0DC2656D, https://asof.is/claim/clm_766F0DC2656D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm.","url":"https://asof.is/claim/clm_766F0DC2656D","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5E2D1C5DC1DC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2024, filed 2025-02-28"}},"to":{"id":"clm_5E2D1C5DC1DC","predicate":"revenue","value":"29,443,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 29,443,000,000 United States dollar\", as of 2025-12-31. Claim clm_5E2D1C5DC1DC, https://asof.is/claim/clm_5E2D1C5DC1DC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm.","url":"https://asof.is/claim/clm_5E2D1C5DC1DC","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2025, filed 2026-02-24"}}}],"rule":"Two states compared by claim id: in both, unchanged; only on to, added; only on from, ended. An ended and an added claim on one predicate are a replacement when the ended one points to the added (superseded_by), or the predicate has exactly one of each and the added begins the day the ended ends. Added rows are labelled for to, ended rows for from. Posts and Hugging Face repos are counted in skipped_posts, not listed.","legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}